There are still significant research gaps in current studies in revealing the specific dynamic changes of mTOR pathway activity, downstream phosphorylation signals, and metabolic crosstalk with immune cells at each stage of AML disease progression (initial diagnosis, remission, and recurrence). Here, MTOR is linked to acute myeloid leukemia.